An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients

• Elizabeth Colston ,

  Roles Data curation, Formal analysis, Writing – original draft, Writing – review & editing

  * E-mail: Elizabeth.Colston@bms.com

  Affiliation Innovative Medicines Development, Bristol-Myers Squibb, Princeton, New Jersey, United States of America

  ⨯
• Dennis Grasela,

  Roles Data curation, Formal analysis, Writing – original draft, Writing – review & editing

  Affiliation Innovative Medicines Development, Bristol-Myers Squibb, Princeton, New Jersey, United States of America

  ⨯
• David Gardiner,

  Roles Data curation, Formal analysis, Writing – review & editing

  Affiliation Infectious Diseases Research and Development, GlaxoSmithKline, Collegeville, Pennsylvania, United States of America

  ⨯
• R. Pat Bucy,

  Roles Data curation, Formal analysis, Investigation, Writing – review & editing

  Affiliation Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America

  ⨯
• Blisse Vakkalagadda,

  Roles Data curation, Formal analysis, Writing – original draft, Writing – review & editing

  Affiliation Clinical Pharmacology and Pharmacometrics, Bristol-Myers Squibb, Hopewell, New Jersey, United States of America

  ⨯
• Alan J. Korman,

  Roles Conceptualization, Data curation, Writing – review & editing

  Affiliation Biologics Discovery California, Bristol-Myers Squibb, Redwood City, California, United States of America

  ⨯
• Israel Lowy

  Roles Conceptualization, Investigation, Writing – original draft, Writing – review & editing

  Affiliation Translational Science and Clinical Oncology, Regeneron Pharmaceuticals, Tarrytown, New York, United States of America

  ⨯